VEGF/VEGFR inhibitors
What are VEGF/VEGFR inhibitors?
List of VEGF/VEGFR inhibitors
View by Brand | Generic
Drug Name | Avg. Rating | Reviews |
---|---|---|
fruquintinib systemic (Pro) | No reviews | |
ramucirumab systemic (Pro) | No reviews | |
tivozanib systemic (Pro) | No reviews | |
vandetanib systemic (Pro) | No reviews | |
ziv-aflibercept systemic (Pro) |
1 review | |
axitinib systemic (Pro) |
2 reviews | |
ponatinib systemic (Pro) |
2 reviews | |
lenvatinib systemic (Pro) |
4 reviews | |
regorafenib systemic (Pro) |
14 reviews | |
sorafenib systemic (Pro) |
15 reviews | |
cabozantinib systemic (Pro) |
26 reviews | |
sunitinib systemic (Pro) |
35 reviews | |
bevacizumab systemic (Pro) |
37 reviews | |
pazopanib systemic (Pro) |
92 reviews | |
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). |
See also
Medical conditions treated or associated with VEGF/VEGFR inhibitors:
- Acute Lymphoblastic Leukemia
- Cervical Cancer
- Chronic Myelogenous Leukemia
- Colorectal Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- Gastric Cancer
- Gastrointestinal Stromal Tumor
- Glioblastoma Multiforme
- Hepatic Tumor
- Hepatocellular Carcinoma
- Non Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Peritoneal Cancer
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Stomach Cancer
- Thyroid Cancer
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.